188
Results-
NewsJerry Liu: A Medical Science Liaison (MSL) Shaping the Future of Healthcare in TaiwanCreated on : - Last modified on :The script of the video.
-
NewsPierre Fabre at the JP Morgan Healthcare Conference: strategic partnerships to accelerate innovation and develop the company's R&D and product portfolio.Created on : - Last modified on :From January 12 to 16, Eric Ducournau and his team were present at the key event for pharmaceuticals, biotechs and healthcare investors. They took part in over 100 meetings with innovative companies, strategic partners and investors. By participating in this latest edition of the JP Morgan Healthcare Conference, Pierre Fabre has reaffirmed its commitment to becoming a global player in the field of innovative medicines.
-
NewsAs major partner of the new Gustave Roussy Prize, Pierre Fabre celebrates innovation in oncologyCreated on : - Last modified on :The new Gustave Roussy International Prize, of which Pierre Fabre Laboratories is the major partner, will be awarded each year to a researcher whose work has demonstrated a major impact on the care of cancer patients.
-
NewsStijn van Oirschot: A Medical Science Liaison (MSL) Driving Medical Excellence in the Netherlands.Created on : - Last modified on :The script of the video.
-
NewsMedical Science Liaisons (MSL) talk about their jobCreated on : - Last modified on :In line with Pierre Fabre Laboratories' vision "Every time we care for a single person, we make the whole world better" the MSL (Medical Science Liaison) role is crucial in enhancing patient care. As a scientific bridge between the medical community and the Pierre Fabre Laboratories, the MSL combines pharmaceutical innovation with medical expertise to develop collaboration with healthcare professionals and optimize daily healthcare practices. The MSL's objectives can be achieved through various missions, including:
-
NewsBLUE MARCH - Colorectal Cancer Awareness MonthCreated on : - Last modified on :
-
Press ReleaseFernando Junoy appointed Pierre Fabre Laboratories’ International Managing DirectorCreated on : - Last modified on :Castres, October 31, 2024 – Pierre Fabre Laboratories announces the appointment of Fernando Junoy as International Managing Director. In this capacity, he reports to Eric Ducournau, Chief Executive Officer, and joins the Executive Committee. Fernando Junoy’s mission will be to boost the international growth for the company. Pierre Fabre Laboratories generates 70% of its revenue internationally and aims to increase this share to 80% by 2030, while consolidating its profitability and cash flow.
-
Press ReleasePierre Fabre receives European approval for BRAFTOVI® (encorafenib)Created on : - Last modified on :Pierre Fabre receives European approval for BRAFTOVI® (encorafenib) in combination with cetuximab for the treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer
-
Press ReleaseChinese beauty company Yatsen acquires iconic skincare brand GALENIC from French group Pierre FabreCreated on : - Last modified on :Guangzhou (China), Castres (France); October 30, 2020 - Chinese beauty company Yatsen has acquired GALENIC, an iconic skincare brand, after reaching an acquisition agreement with French pharmaceutical and dermo-cosmetic group Pierre Fabre. The take-over will be effective on November 1st, 2020. Pierre Fabre will own a minority stake of 10% in the affiliate created by Yatsen to host Galénic assets in Europe.
-
Press ReleaseCreation of a research partnership between Pierre Fabre and Y-Biologics for the development of new immunotherapies based on monoclonal antibodiesCreated on : - Last modified on :Daejeon (South Korea), Castres (France), November 20th, 2020 – The South Korean biotech company Y-Biologics and the French pharmaceutical group Pierre Fabre have announced their plans to form a strategic partnership in the field of immuno-oncology research. The decision has been acknowledged through a letter of intent signed by both parties and will be confirmed in the coming months through a detailed agreement. The collaboration is set to run for three years, with the possibility of a two-year extension.
We take care of life by designing and developing innovative solutions inspired by consumers and patients, and contributing to the well-being of everyone from health to beauty.